![](\"https:\/\/mms.businesswire.com\/media\/20260519682641\/en\/2809012\/22\/Coco_Douaihy_CG-Life_Chief_Creative_Officer.jpg\")
<\/a>![](\"https:\/\/mms.businesswire.com\/media\/20260519682641\/en\/2809012\/21\/Coco_Douaihy_CG-Life_Chief_Creative_Officer.jpg\")
<\/a>![](\"https:\/\/mms.businesswire.com\/media\/20260519682641\/en\/2809025\/22\/CG-Life-Logo_Black.jpg\"){kind=logo}
<\/a>![](\"https:\/\/mms.businesswire.com\/media\/20260519682641\/en\/2809025\/21\/CG-Life-Logo_Black.jpg\"){kind=logo}
<\/a>\nDouaihy brings more than 26 years of experience leading award-winning creative for numerous pharmaceutical and medical marketing agencies. Most recently, she served as Global CCO, Health at Dentsu International. Before Dentsu, she was the Global CCO of Evoke and ECD at Digitas Health. In 2024, she was appointed as Pharma Jury President at Cannes Lions and was recognized by MM+M as one of the Healthcare Marketing Influencer 25, Class of 2024.<\/p>
\n\u201cPartnering with visionary companies to help bring transformative treatments to patients with rare and hard-to-treat diseases demands that a creative team be fueled by empathy,\u201d said Douaihy. \u201cOur team is deeply engaged in understanding not just the unmet clinical need, but the realities that those living with these diseases face every day. Rare disease demands rare creative \u2014 not louder but sharper, not safer but braver, not more but more meaningful. And we\u2019re resolute in our commitment to making a difference.\u201d<\/p>
\n\u201cBiopharma companies today are navigating an environment of increasingly complex launches, competitive landscapes, and stakeholder expectations. As clients rely on CG Life to deliver truly disruptive and innovative approaches for bringing new therapies to market, we must ensure that we are consistently offering them insightful and visionary creative direction and ideas,\u201d said David Ormesher<\/b>, CEO of CG Life. \u201cWith Coco at the head of our creative engines, CG Life will drive a creative vision for biopharma companies advancing and launching therapies in rare disease and high-unmet-need categories.\u201d<\/p>
\nCG Life\u2019s promotion of Chris Weber to CSO underscores the agency\u2019s belief that strong strategy is foundational to helping biopharma companies navigate critical growth and commercialization milestones. Bringing more than 30 years of healthcare agency experience to the role, he will continue to broaden CG Life\u2019s strategic offering for clients across the biopharma and broader life sciences sector.<\/p>
\n\u201cFor the past two years, Chris and his team have been instrumental in strengthening how CG Life partners with its biopharma and life science clients through deep strategic counsel and insight,\u201d Ormesher continued. \u201cHe brings an intangible blend of experience, smarts, and leadership that is indispensable as we continue to elevate both our agency and the work we deliver for clients.\u201d<\/p>
\nAbout CG Life<\/b><\/p>
\nFounded in 2003, CG Life is a specialized pharma agency built for the unique challenges of bringing therapies for rare and hard-to-treat diseases to market, where traditional commercialization models often fall short. CG Life partners with biopharma companies to navigate the complexity of rare disease commercial launches by combining deep scientific expertise, strategy-led activation of physician and patient communities, and results-driven engagement to support what's best for patients. The result is faster, more effective launches in markets where insight, creativity, and credibility determine success.<\/p>
\nBegin your journey at CGLife.com<\/a>.<\/p>